The current diagnosis of AD is mainly based on clinical assessment (clinical symptoms and history of disease), neuropsychological scale tests (MMSE, MoCA, ADAS-cog, CDR, and GDS) and neuroimaging (CT, MRI, and PET), as well as biomarker testing (concentrations of cerebrospinal fluid biomarkers Aβ, T-tau, and P-tau). This evidence concerns the gene MAPT and Alzheimer disease.